HRS-5632
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
October 01, 2025
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
(clinicaltrials.gov)
- P2 | N=200 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular
September 23, 2025
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
(clinicaltrials.gov)
- P2 | N=200 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
New P2 trial • Cardiovascular
April 08, 2025
HRS-5632-101: A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=50 | Active, not recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Dyslipidemia • Metabolic Disorders
December 13, 2024
HRS-5632-101: A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
New P1 trial • Dyslipidemia • Metabolic Disorders
1 to 4
Of
4
Go to page
1